WO2014106804A3 - Compositions et procédés de traitement du syndrome métabolique et du diabète - Google Patents
Compositions et procédés de traitement du syndrome métabolique et du diabète Download PDFInfo
- Publication number
- WO2014106804A3 WO2014106804A3 PCT/IB2013/061384 IB2013061384W WO2014106804A3 WO 2014106804 A3 WO2014106804 A3 WO 2014106804A3 IB 2013061384 W IB2013061384 W IB 2013061384W WO 2014106804 A3 WO2014106804 A3 WO 2014106804A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compositions
- diabetes
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La présente invention concerne des composés de formule I et de formule II ou leurs sels pharmaceutiquement acceptables, ainsi que leurs polymorphes, leurs solvates, leurs énantiomères, leurs stéréoisomères et leurs hydrates. Les compositions pharmaceutiques comprennent une quantité efficace de composés de formule I ou de formule II; et des procédés de traitement ou de prévention du syndrome métabolique et du diabète. Les compositions pharmaceutiques peuvent être formulées pour une administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, sous la forme d'un sirop, ou pour une injection. Ces compositions peuvent être utilisées pour le traitement du diabète sucré, de l'obésité, de troubles lipidiques, de la douleur neuropathique, de l'hypertriglycéridémie, de l'hyperglycémie, de l'hyperinsulinémie et de l'insulinorésistance.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN52/CHE/2013 | 2013-01-04 | ||
IN52CH2013 | 2013-01-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014106804A2 WO2014106804A2 (fr) | 2014-07-10 |
WO2014106804A3 true WO2014106804A3 (fr) | 2017-04-13 |
Family
ID=51062520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/061384 WO2014106804A2 (fr) | 2013-01-04 | 2013-12-28 | Compositions et procédés de traitement du syndrome métabolique et du diabète |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014106804A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7208982B2 (ja) | 2017-09-20 | 2023-01-19 | チオジェネシス セラピューティクス, インコーポレイテッド | システアミン感受性障害の治療方法 |
JP7418958B2 (ja) | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス, インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106883158B (zh) * | 2015-12-15 | 2019-08-23 | 中国科学院广州生物医药与健康研究院 | 生物可降解的氨基脂质类化合物及其制备方法和应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131995A1 (fr) * | 1983-07-19 | 1985-01-23 | Maggioni-Winthrop S.P.A. | Composés à activité hypolipémique |
US5120738A (en) * | 1989-10-06 | 1992-06-09 | Fujirebio Inc. | Pantothenic acid derivatives |
WO1995011673A1 (fr) * | 1993-10-27 | 1995-05-04 | Oculon Corporation | Composes et procedes de traitement de la drepanocytose |
US20010002404A1 (en) * | 1996-05-22 | 2001-05-31 | Webb Nigel L. | Fatty acid-pharmaceutical agent conjugates |
US20100184730A1 (en) * | 2008-07-08 | 2010-07-22 | Vu Chi B | Fatty Acid Acylated Salicylates and Their Uses |
WO2011106688A1 (fr) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Conjugués de bis-acide gras et leurs utilisations |
US20120184585A1 (en) * | 2009-09-01 | 2012-07-19 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
WO2012149352A1 (fr) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Dérivés de guanidine d'acide gras et de guanidine de salicylate et leurs utilisations |
WO2014087307A2 (fr) * | 2012-12-04 | 2014-06-12 | Mahesh Kandula | Compositions et procédés pour le traitement du syndrome métabolique et du diabète |
-
2013
- 2013-12-28 WO PCT/IB2013/061384 patent/WO2014106804A2/fr active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131995A1 (fr) * | 1983-07-19 | 1985-01-23 | Maggioni-Winthrop S.P.A. | Composés à activité hypolipémique |
US5120738A (en) * | 1989-10-06 | 1992-06-09 | Fujirebio Inc. | Pantothenic acid derivatives |
WO1995011673A1 (fr) * | 1993-10-27 | 1995-05-04 | Oculon Corporation | Composes et procedes de traitement de la drepanocytose |
US20010002404A1 (en) * | 1996-05-22 | 2001-05-31 | Webb Nigel L. | Fatty acid-pharmaceutical agent conjugates |
US20100184730A1 (en) * | 2008-07-08 | 2010-07-22 | Vu Chi B | Fatty Acid Acylated Salicylates and Their Uses |
US20120184585A1 (en) * | 2009-09-01 | 2012-07-19 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
WO2011106688A1 (fr) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Conjugués de bis-acide gras et leurs utilisations |
WO2012149352A1 (fr) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Dérivés de guanidine d'acide gras et de guanidine de salicylate et leurs utilisations |
WO2014087307A2 (fr) * | 2012-12-04 | 2014-06-12 | Mahesh Kandula | Compositions et procédés pour le traitement du syndrome métabolique et du diabète |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7418958B2 (ja) | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス, インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
JP7208982B2 (ja) | 2017-09-20 | 2023-01-19 | チオジェネシス セラピューティクス, インコーポレイテッド | システアミン感受性障害の治療方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2014106804A2 (fr) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014087307A3 (fr) | Compositions et procédés pour le traitement du syndrome métabolique et du diabète | |
WO2013175377A3 (fr) | Compositions et méthodes pour le traitement de la mucosite | |
WO2013175376A3 (fr) | Compositions et méthodes de traitement de la douleur locale | |
WO2014068463A3 (fr) | Compositions et procédés de traitement d'une inflammation et de troubles métaboliques | |
MX2019007713A (es) | Composiciones y metodos para el tratamiento del dolor cronico. | |
PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
WO2014174425A3 (fr) | Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques | |
WO2016046680A3 (fr) | Compositions et procédés de traitement de maladies métaboliques hépatiques | |
WO2014106804A3 (fr) | Compositions et procédés de traitement du syndrome métabolique et du diabète | |
WO2013175359A3 (fr) | Compositions et méthodes pour le traitement de la sclérose en plaques | |
WO2014091384A3 (fr) | Compositions et méthodes pour le traitement de la mucosite | |
WO2014080307A3 (fr) | Compositions et procédés pour le traitement du diabète et du pré-diabète | |
WO2014006529A3 (fr) | Compositions et méthodes de traitement de la douleur modérée à aiguë | |
WO2014195810A3 (fr) | Compositions et méthodes pour le traitement du diabète et du prédiabète | |
WO2014087323A3 (fr) | Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques | |
WO2014195850A3 (fr) | Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques | |
WO2013167998A3 (fr) | Compositions et méthodes de traitement de troubles autonomiques et autres troubles neurologiques | |
WO2014097137A3 (fr) | Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques | |
WO2013175344A3 (fr) | Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde | |
MX2019005568A (es) | Composiciones y metodos para el tratamiento de polipos gastrointestinales. | |
WO2013167989A3 (fr) | Compositions et méthodes de traitement de troubles neurologiques | |
WO2014068459A3 (fr) | Compositions et méthodes de traitement de la douleur et de maladies neurologiques | |
WO2014083476A3 (fr) | Compositions et méthodes pour le traitement de troubles métaboliques et lipidiques | |
WO2015015403A3 (fr) | Compositions et méthodes utilisables en vue du traitement du diabète et du pré-diabète | |
WO2014106805A3 (fr) | Conjugués d'acides gras et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13870022 Country of ref document: EP Kind code of ref document: A2 |